The primary objective of the research group is to take a multidisciplinary approach to studying the molecular, cellular, and synaptic mechanisms underlying numerous neurodegenerative and psychiatric disorders. The multidisciplinary Team of basic and clinical researchers is primarily focused on identifying new predictive, diagnostic, and/or prognostic biomarkers, therapeutic targets, and potential treatments for various neurological conditions characterized by neuronal degeneration and/or synaptic abnormalities. To this end, the group utilizes various cellular and animal models of different neuropathologies—primarily motor disorders such as ALS—along with the necessary technology to conduct studies ranging from the subcellular level to the whole organism. Using pharmacological and genetic tools, we can identify and validate new therapeutic strategies at the preclinical level for subsequent translation to patients. The group also aims to develop and validate protocols for the determination of clinically valid biomarkers.